NodThera Looks To Compete In Long-Awaited Inflammasome Field With Parkinson’s Therapy

Will Face Competition From Roche

Brain scan
NodThera has chosen Parkinson's disease to be its first target with NT-0796. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapy Areas